Health and economic impact of improved glucose, blood pressure and lipid control among German adults with type 2 diabetes: a modelling study
Authors' conclusion
Sustained improvements in HbA1c, SBP and LDL-cholesterol control among diabetes patients in Germany can lead to substantial health benefits and reduce healthcare expenditures.
Study context
- Population
- German adults with T2D; model parameterised with German data
- Comparison
- Improved HbA1c, systolic BP (SBP) or LDL-C control vs current control
- Outcome
- Healthcare costs and QALYs
- Follow-up
- Over 5, 10 and 30 years
Methodological detailsUKPDS Outcomes Model 2, patient-level simulation, 5-, 10- and 30-year horizons
- UKPDS Outcomes Model 2
- Patient-level simulation
- 5-, 10- and 30-year horizons
Main finding
As reported in the abstract
Permanent reduction of HbA1c, SBP, LDL-C: per-person savings
€121, €238 and €34
Permanent reduction of HbA1c, SBP, LDL-C: Quality-adjusted life year (QALYs) gained
0.01, 0.02 and 0.015
Achieving guideline targets for HbA1c, SBP, LDL-C (in those not meeting them): reduced expenditure
€451, €507 and €327
Achieving guideline targets for HbA1c, SBP, LDL-C: additional QALYs
0.03, 0.05 and 0.06
Further findings
Nationwide healthcare cost reduction, achieving guideline targets for HbA1c, SBP and LDL-C
- Reduction in healthcare costs
- over €1.9 billion
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →